tradingkey.logo
๎™

Arcellx Inc

ACLX
65.540USD
-0.460-0.70%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
3.79B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Arcellx Inc ํšŒ์‚ฌ

Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Arcellx Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ACLX
ํšŒ์‚ฌ ์ด๋ฆ„Arcellx Inc
์ƒ์žฅ์ผFeb 04, 2022
CEOElghandour (Rami)
์ง์› ์ˆ˜163
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 04
์ฃผ์†Œ800 Bridge Parkway
๋„์‹œREDWOOD CITY
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ94065
์ „ํ™”12403270603
์›น์‚ฌ์ดํŠธhttps://www.arcellx.com/
์ข…๋ชฉ ์ฝ”๋“œ ACLX
์ƒ์žฅ์ผFeb 04, 2022
CEOElghandour (Rami)

Arcellx Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Rami Elghandour
Mr. Rami Elghandour
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
617.92K
-46.95%
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
21.66K
--
Ms. Michelle Gilson
Ms. Michelle Gilson
Chief Financial Officer
Chief Financial Officer
8.47K
-57.19%
Mr. Andrew H. Galligan
Mr. Andrew H. Galligan
Independent Director
Independent Director
5.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
2.01K
+374.06%
Dr. Kavita Patel, M.D.
Dr. Kavita Patel, M.D.
Independent Director
Independent Director
--
--
Ms. Olivia C. Ware
Ms. Olivia C. Ware
Independent Director
Independent Director
--
--
Ms. Jill Carroll
Ms. Jill Carroll
Independent Director
Independent Director
--
--
Ms. Kristin Myers
Ms. Kristin Myers
Independent Director
Independent Director
--
--
Dr. Christopher R. Heery, M.D.
Dr. Christopher R. Heery, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Rami Elghandour
Mr. Rami Elghandour
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
617.92K
-46.95%
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
21.66K
--
Ms. Michelle Gilson
Ms. Michelle Gilson
Chief Financial Officer
Chief Financial Officer
8.47K
-57.19%
Mr. Andrew H. Galligan
Mr. Andrew H. Galligan
Independent Director
Independent Director
5.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
2.01K
+374.06%
Dr. Kavita Patel, M.D.
Dr. Kavita Patel, M.D.
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

FY2025Q2
FY2025Q1
FY2024
FY2023
FY2023Q1
FY2021
FY2020
FY2019
FY2018
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์ง€์—ญ๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
United States
7.55M
0.00%
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Nov 16
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Nov 16
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
T. Rowe Price Investment Management, Inc.
16.61%
Gilead Sciences Inc
11.62%
Fidelity Management & Research Company LLC
9.36%
Paradigm BioCapital Advisors LP
8.04%
The Vanguard Group, Inc.
6.75%
๊ธฐํƒ€
47.62%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
T. Rowe Price Investment Management, Inc.
16.61%
Gilead Sciences Inc
11.62%
Fidelity Management & Research Company LLC
9.36%
Paradigm BioCapital Advisors LP
8.04%
The Vanguard Group, Inc.
6.75%
๊ธฐํƒ€
47.62%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
49.52%
Venture Capital
16.81%
Hedge Fund
15.82%
Investment Advisor/Hedge Fund
15.04%
Corporation
11.62%
Private Equity
4.36%
Research Firm
2.05%
Individual Investor
1.19%
Bank and Trust
0.23%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
441
60.19M
107.73%
+3.27M
2025Q3
457
56.92M
115.34%
-1.91M
2025Q2
440
55.23M
110.30%
-248.28K
2025Q1
433
55.56M
106.71%
-3.07M
2024Q4
424
53.15M
105.55%
+1.98M
2024Q3
391
50.27M
106.69%
-1.02M
2024Q2
368
52.42M
103.43%
+3.23M
2024Q1
351
49.13M
103.29%
-5.40M
2023Q4
314
49.14M
109.15%
-782.40K
2023Q3
282
49.93M
110.29%
-824.73K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
T. Rowe Price Investment Management, Inc.
6.28M
11.32%
+4.33M
+222.88%
Aug 31, 2025
Gilead Sciences Inc
6.72M
12.12%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.57M
10.04%
-263.72K
-4.52%
Jun 30, 2025
Paradigm BioCapital Advisors LP
4.65M
8.38%
+156.98K
+3.49%
Jun 30, 2025
The Vanguard Group, Inc.
3.94M
7.1%
-40.27K
-1.01%
Jun 30, 2025
New Enterprise Associates (NEA)
3.05M
5.49%
-700.00K
-18.69%
Aug 14, 2025
RA Capital Management, LP
3.04M
5.48%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.77M
5%
-437.78K
-13.63%
Jun 30, 2025
Perceptive Advisors LLC
2.48M
4.47%
-448.48K
-15.32%
Jun 30, 2025
SR One Capital Management, LP
2.35M
4.23%
--
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Genomics Immunology and Healthcare ETF
4.98%
Tema Oncology ETF
4.19%
ALPS Medical Breakthroughs ETF
1.96%
Harbor Human Capital Factor US Small Cap ETF
1.38%
WisdomTree BioRevolution Fund
1.13%
State Street SPDR S&P Biotech ETF
1.08%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
iShares Health Innovation Active ETF
0.75%
Direxion Daily S&P Biotech Bull 3X Shares
0.67%
ProShares Ultra Nasdaq Biotechnology
0.49%
๋” ๋ณด๊ธฐ
iShares Genomics Immunology and Healthcare ETF
๋น„์œจ4.98%
Tema Oncology ETF
๋น„์œจ4.19%
ALPS Medical Breakthroughs ETF
๋น„์œจ1.96%
Harbor Human Capital Factor US Small Cap ETF
๋น„์œจ1.38%
WisdomTree BioRevolution Fund
๋น„์œจ1.13%
State Street SPDR S&P Biotech ETF
๋น„์œจ1.08%
Virtus LifeSci Biotech Clinical Trials ETF
๋น„์œจ0.92%
iShares Health Innovation Active ETF
๋น„์œจ0.75%
Direxion Daily S&P Biotech Bull 3X Shares
๋น„์œจ0.67%
ProShares Ultra Nasdaq Biotechnology
๋น„์œจ0.49%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Arcellx Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Arcellx Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
T. Rowe Price Investment Management, Inc.๋Š” 6.28M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 11.32%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Gilead Sciences Inc๋Š” 6.72M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 12.12%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Fidelity Management & Research Company LLC๋Š” 5.57M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 10.04%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Paradigm BioCapital Advisors LP๋Š” 4.65M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 8.38%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 3.94M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 7.10%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Arcellx Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Arcellx Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
T. Rowe Price Investment Management, Inc.
Gilead Sciences Inc
Fidelity Management & Research Company LLC์ž…๋‹ˆ๋‹ค.

Arcellx Inc(ACLX)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Arcellx Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 441๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 60.19M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 107.73%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -7.60% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Arcellx Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2025Q2 ๊ธฐ์ค€, Arcellx Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™